Clinical studies are ongoing to develop tissue lysate array conditions to quantify measures of the microenvironment in clinical samples. Surrogate measurements of vascularity, such as stromal CD31 signals, and assessment of activation of receptor tyrosine kinase pathways and intracellular signaling nodal activity, will be assessed in both tumor epithelium and stroma from the same biopsy specimens. These specimens will be obtained before and during treatment with small molecule kinase inhibitors. Application of CD31 to protein array technology is nearing completion with a cross validation using clinical samples impending. Application of the array technology to laboratory study of angiogenesis is in the planning stages. Studies with CAI are ongoing collaboratively, assessing the biological and biochemical results of its combination with COX2 inhibitors, inhibitors of receptor tyrosine kinases such as imatinib, and also with ECGC, the anti-oxidant component of green tea. Use of CAI for ophthalmologic disease has been licensed and a CRADA is also under development. CAI will be tested therapeutically for benefit in macular degeneration. This comprehensive approach to angiogenesis and microenvironment study in the laboratory and patient samples will provide opportunity for proof of principle of molecularly targeted agents in stromal therapy and will complement our continuing clinical work with signal transduction inhibition therapy.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC009374-14
Application #
7292055
Study Section
(LP)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Hoskins, Ebony; Rodriguez-Canales, Jaime; Hewitt, Stephen M et al. (2011) Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol 122:656-62
Balkwill, Frances R; Ashworth, Alan; Bast, Robert C et al. (2006) 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res 66:2904-6
Alessandro, Riccardo; Di Bella, Maria Antonietta; Flugy, Anna Maria et al. (2006) Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasis. Virchows Arch 449:48-61
Davidson, Ben; Espina, Virginia; Steinberg, Seth M et al. (2006) Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12:791-9
Azad, Nilofer S; Rasool, Nabila; Annunziata, Christina M et al. (2006) Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics 5:1819-29
Kassis, Jareer N; Guancial, Elizabeth A; Doong, Howard et al. (2006) CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Exp Cell Res 312:2962-71
Stevens, Ellen V; Raffeld, Mark; Espina, Virginia et al. (2005) Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer 103:2313-9
Kassis, Jareer; Klominek, Julius; Kohn, Elise C (2005) Tumor microenvironment: what can effusions teach us? Diagn Cytopathol 33:316-9
Perabo, Frank G E; Demant, Andre W; Wirger, Andreas et al. (2005) Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model. Anticancer Res 25:725-9
Winters, Mary E; Mehta, Arpita I; Petricoin 3rd, Emanuel F et al. (2005) Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res 65:3853-60

Showing the most recent 10 out of 22 publications